Ali Javaheri, Ahmed Diab, Lei Zhao, Chenao Qian, Jordana B Cohen, Payman Zamani, Anupam Kumar, Zhaoqing Wang, Christina Ebert, Joseph Maranville, Erika Kvikstad, Michael Basso, Vanessa van Empel, A Mark Richards, Robert N Doughty, Ernst Rietzschel, Karl Kammerhoff, Joseph Gogain, Peter Schafer, Dietmar A Seiffert, David A Gordon, Francisco Ramirez-Valle, Douglas L Mann, Thomas P Cappola, Julio A Chirinos
BACKGROUND: The TOPCAT trial (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial) suggested clinical benefits of spironolactone treatment among patients with heart failure with preserved ejection fraction enrolled in the Americas. However, a comprehensive assessment of biologic pathways impacted by spironolactone therapy in heart failure with preserved ejection fraction has not been performed. METHODS: We conducted aptamer-based proteomic analysis utilizing 5284 modified aptamers to 4928 unique proteins on plasma samples from TOPCAT participants from the Americas (n=164 subjects with paired samples at baseline and 1 year) to identify proteins and pathways impacted by spironolactone therapy in heart failure with preserved ejection fraction...
September 2022: Circulation. Heart Failure